NEW YORK, Dec. 19, 2017 /PRNewswire/ -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. ("Novavax " or the "Company") (NASDAQ: NVAX). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/nvax.
The investigation concerns whether Novavax and certain of its officers and/or directors have violated Sections federal securities laws.
In November 2017, Novavax projected a year-end release for top-line data from the Company's Phase 1/2 clinical trial of its NanoFlu Vaccine. Then, on December 19, 2017, Novavax announced that a "complete package" will not be completed and released until February 2018. Novavax advised investors that "the wild-type viruses necessary to assess immunogenicity of the vaccines to circulating strains have been difficult to obtain, grow and maintain genetic stability." On this news, Novavax's share price has fallen sharply during intraday trading on December 19, 2017.
If you are aware of any facts relating to this investigation, or purchased shares of Novavax, you can assist this investigation by visiting the firm's site: www.bgandg.com/nvax. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
SOURCE Bronstein, Gewirtz & Grossman, LLC